Last SFr.86.80 CHF
Change Today +1.15 / 1.34%
Volume 55.6K
As of 1:52 PM 10/22/14 All times are local (Market data is delayed by at least 15 minutes).

basilea pharmaceutica-reg (BSLN) Snapshot

Previous Close
Day High
Day Low
52 Week High
02/12/14 - SFr.129.80
52 Week Low
10/16/14 - SFr.79.75
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield

Related News

No related news articles were found.

basilea pharmaceutica-reg (BSLN) Related Businessweek News

No Related Businessweek News Found

basilea pharmaceutica-reg (BSLN) Details

Basilea Pharmaceutica AG, an integrated biopharmaceutical company, focuses on the discovery and development of pharmaceutical products in the therapeutic areas of bacterial infections, fungal infections, and oncology in Switzerland and China. The company markets Toctino, a therapy for the treatment of adult patients with severe chronic hand eczema, who do not respond to potent topical corticosteroids. It is also developing Isavuconazole, a Phase III development antifungal drug for the treatment of invasive fungal infections; and Ceftobiprole, a bactericidal antibiotic for the treatment of hospital and community-acquired pneumonia, which is under regulatory review. In addition, the company is developing BAL30072, a monosulfactam antibiotic with bactericidal activity against multidrug-resistant gram-negative bacteria under Phase I clinical development; and BAL101553, a small-molecule anti-cancer drug in Phase I clinical development. Basilea Pharmaceutica AG was founded in 2000 and is headquartered in Basel, Switzerland.

200 Employees
Last Reported Date: 02/6/14
Founded in 2000

basilea pharmaceutica-reg (BSLN) Top Compensated Officers

Chief Executive Officer
Total Annual Compensation: SFr.888.4K
Compensation as of Fiscal Year 2013.

basilea pharmaceutica-reg (BSLN) Key Developments

Basilea Pharmaceutica AG Presents at Bank of America Merrill Lynch Global Healthcare Conference, Sep-17-2014

Basilea Pharmaceutica AG Presents at Bank of America Merrill Lynch Global Healthcare Conference, Sep-17-2014 . Venue: Bank of America Merrill Lynch Financial Centre, London, United Kingdom.

European Medicines Agency Accepts Basilea's Isavuconazole Marketing Authorization Application for Review

Basilea Pharmaceutica Ltd. announced that the European Medicines Agency has accepted its isavuconazole Marketing Authorization Application for review. Basilea's MAA seeks approval of isavuconazole for the treatment of invasive aspergillosis and mucormycosis (zygomycosis) in adults. The EMA will review the application under the centralized marketing authorization procedure. If approved by the EMA, isavuconazole would receive marketing authorization in all 28 member states of the European Union, as well as in Iceland, Liechtenstein and Norway. Isavuconazole is an investigational once-daily intravenous and oral broad-spectrum antifungal for the potential treatment of life-threatening invasive fungal infections which predominantly occur in immunocompromised patients such as cancer patients undergoing chemotherapy. It has EU and U.S. orphan drug status for the treatment of invasive aspergillosis and mucormycosis. In the U.S., isavuconazole was granted FDA fast-track status and designated a Qualified Infectious Disease Product for invasive aspergillosis, mucormycosis and candidiasis under the U.S. GAIN Act.

Basilea Pharmaceutica Ltd. Appoints David Veitch as Chief Commercial Officer, Effective September 1, 2014

Basilea Pharmaceutica Ltd. announced that it has appointed David Veitch as Chief Commercial Officer of the company. Mr. Veitch will join the company on September 1, 2014. As a member of the management committee, he will be responsible for leading the company's commercial operations including sales, marketing, pricing and market access, reporting to Chief Executive Officer Ronal Scott. Most recently he was President European Operations at Savient Pharmaceuticals.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
BSLN:SW SFr.86.80 CHF +1.15

BSLN Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for BSLN.
View Industry Companies

Industry Analysis


Industry Average

Valuation BSLN Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 20.7x
Price/Book 11.8x
Price/Cash Flow NM Not Meaningful
TEV/Sales 14.9x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact BASILEA PHARMACEUTICA-REG, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at